<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478595</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6647</org_study_id>
    <nct_id>NCT00478595</nct_id>
  </id_info>
  <brief_title>Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug</brief_title>
  <acronym>SYMPHONY</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Monotherapy Inadequately Controlled With Oral Anti-diabetic Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of Rimonabant (SR141716)
      compared to placebo on change in HbA1c and on relative change in body weight over 52 weeks in
      obese type 2 diabetic patients on monotherapy inadequately controlled with oral anti-diabetic
      drug (sulfonylurea or α-glucosidase inhibitor).

      The secondary objectives are:

        -  To evaluate the effect of Rimonabant compared to placebo on other parameters related to
           the glucose control, waist circumference, Body Mass Index and metabolic parameters;

        -  To evaluate the safety and tolerability of Rimonabant compared to placebo;

        -  To evaluate the pharmacokinetics of Rimonabant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration per patient will be approximately 69 weeks including a 52-week
      double-blind treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision taken in light of demands by certain national health authorities
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline in HbA1C</measure>
    <time_frame>Baseline to week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative change from baseline in in body weight</measure>
    <time_frame>Baseline to week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in waist circumference</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline in Triglycerides and HDL-cholesterol</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: overview of adverse events</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">458</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Rimonabant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rimonabant 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for Rimonabant) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Rimonabant</arm_group_label>
    <other_name>SR141716</other_name>
    <other_name>Acomplia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Rimonabant)</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-diabetic monotherapy</intervention_name>
    <description>Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period</description>
    <arm_group_label>Rimonabant</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus patients on monotherapy with oral anti-diabetic drug
             (sulfonylurea or α-glucosidase inhibitor)

          -  HbA1C ≥ 7.0 % and ≤ 10.0 %

          -  Body Mass Index ≥ 25 kg/m²

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Within 12 weeks prior to screening visit: use of oral antidiabetic drugs (other than a
             sulfonylurea or alpha-glucosidase inhibitor) and/or insulin, of anti-obesity drugs or
             other drugs for weight reduction

          -  Within 4 weeks prior to screening visit: administration of systemic long-acting
             corticosteroids or prolonged use (more than one week) of other systemic
             corticosteroids, change in lipid lowering treatment

          -  Secondary obesity

          -  Primary hyperlipidemia

          -  Positive serum pregnancy test in females of childbearing potential

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2007</study_first_posted>
  <disposition_first_submitted>June 1, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 1, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 6, 2016</disposition_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obese</keyword>
  <keyword>diabetes</keyword>
  <keyword>cannabinoid-1 receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

